Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEC003M in advanced stage prostate cancer
NCT07657806Phase 1Recruiting
- Sponsor
- Hangzhou DAC Biotech
- Start
- Aug 2026
- Primary completion
- Mar 2029
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DEC003M in prostate cancer (PCa), sponsored by Hangzhou DAC Biotech. Primary endpoints: Adverse Events at 1 year, Dose-Limiting Toxicity at 3 weeks and 1 more. Started Aug 2026; status: recruiting.
02
Drugs
DEC003M
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07657806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07657806.